Olema Pharmaceuticals, Inc.
NASDAQ:OLMABiotechnology
Healthcare
$7.06 -2.70%
-$0.26 today
- Market cap
- $618.50M
- Beta
- 2.00
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$1.80
52W Low $4.02High $36.26
Volume 1.18M
Average 1.27M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$146.72M
FY 2025 · Annual
Investing Cash Flow
-$155.76M
FY 2025 · Annual
Financing Cash Flow
$211.30M
FY 2025 · Annual
-21.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.1M) | (104.79M) | (96.66M) | (129.47M) | (162.45M) |
| Depreciation & Amortization | 1.66M | 1.66M | 377K | 393K | 490K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 17.26M | 22.58M | 17.59M |
| Change in Working Capital | 2.83M | 3.02M | (589K) | 9.16M | 2.78M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (683K) | 351K | 2.32M | 2.51M | 4.6M |
| Other Working Capital | 3.51M | 2.67M | (2.91M) | 6.65M | (1.82M) |
| Other Non-Cash Items | 15.91M | 18.04M | (4.12M) | (7.02M) | (5.12M) |
| Operating Cash Flow | (50.69M) | (82.07M) | (83.73M) | (104.35M) | (146.72M) |
| Capital Expenditures | (1.58M) | (363K) | 0 | (159K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (486.97M) | (213.66M) | (255.63M) | (394.96M) | (500.72M) |
| Sales of Investments | 213.1M | 305.5M | 250.76M | 301.59M | 344.96M |
| Other Investing Activities | 0 | 0 | 14K | 0 | 0 |
| Investing Cash Flow | (275.44M) | 91.48M | (4.85M) | (93.53M) | (155.76M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 3M |
| Common Stock Issued | 1.39M | 476K | 129.74M | 266.29M | 208.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 3.68M | 2.53M | 0 |
| Financing Cash Flow | 1.39M | 476K | 133.42M | 268.82M | 211.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (324.74M) | 9.89M | 44.84M | 70.94M | (91.18M) |
| Free Cash Flow | (52.27M) | (82.43M) | (83.73M) | (104.51M) | (146.72M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$162.5M
+ D&A$490.0K
+ Stock-Based Comp$17.6M
+ Deferred Tax$0
+ Working Capital$2.8M
- Other Non-Cash-$5.1M
= Operating Cash Flow-$146.7M
- Capex$0
= Free Cash Flow-$146.7M
Analysis
FY2025 free cash flow is -$146.7M. FCF conversion is 90.3% of net income. Operating cash flow was -$146.7M, with capex of $0. The largest bridge item is Stock-Based Comp at $17.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 16, 2026 | |
| 8-K | Current report | Oct 15, 2026 |
Does OLMA generate free cash flow?
Olema Pharmaceuticals, Inc. (OLMA) generated -$146.72M of free cash flow in fiscal 2025.
How much operating cash flow does OLMA produce?
Operating cash flow was -$146.72M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.